Disease · HP_0001395
Hepatic fibrosis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Hepatic fibrosis. Diseases, record HP_0001395. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001395
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hepatic fibrosis
- Open Targets ID
- HP_0001395
- Other names
- Liver fibrosis
- Highest stage of its drugs
- Approval, for 2 of its 77 drugs, from TTD
Source Open Targets
Drugs77
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ADEMETIONINE | CHEMBL1088977 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| INTERFERON GAMMA-1B | CHEMBL1201564 | Protein | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| HYDRONIDONE | CHEMBL4297288 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PEGINTERFERON ALFA-2A | CHEMBL1201560 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CENICRIVIROC | CHEMBL2110727 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CANDESARTAN | CHEMBL1016 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DACLATASVIR | CHEMBL2023898 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SURVODUTIDE | CHEMBL5314776 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ZINC SULFATE | CHEMBL1200929 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ELBASVIR | CHEMBL3039514 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 77
See all 77 drugsTargets128
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR1H4 | Bile acid receptor | 4 | Bile acid receptor FXR agonist | Phase 2 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 3 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 3 | Glucagon-like peptide 1 receptor agonist | Phase 3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 1/2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor | Phase 1/2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| FGF1 | FGF1/KLB | 2 | FGF1/KLB activator; FGF1/KLB agonist | Phase 2 | https://conductscience.org/library/genes/2246 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Phase 3 | https://conductscience.org/library/genes/3454 | Drugs and targets |
1 to 10 of 128
See all 128 targetsTrials66
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03028740 | AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) | Phase 3 | 1,778 | 2022-03-10 | Nonalcoholic Steatohepatitis | CENICRIVIROC | Its record names the disease | ClinicalTrials.gov |
| NCT03449446 | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 395 | 2020-12-03 | Nonalcoholic Steatohepatitis | CILOFEXOR, FIRSOCOSTAT, SELONSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT04771273 | A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Phase 2 | 295 | 2024-12-03 | Non-alcoholic Steatohepatitis (NASH) | SURVODUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02217475 | Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis | Phase 2 | 289 | 2019-05-10 | Nonalcoholic Steatohepatitis | CENICRIVIROC | Its record names the disease | ClinicalTrials.gov |
| NCT00244751 | Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects | Phase 2 | 265 | 2017-12-11 | Cirrhosis, Liver | FARGLITAZAR | Its record names the disease | ClinicalTrials.gov |
| NCT04065841 | Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. | Phase 2 | 234 | 2023-12-26 | Non Alcoholic Steatohepatitis (NASH) | LICOGLIFLOZIN, TROPIFEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT03486899 | A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis | Phase 2 | 197 | 2022-09-09 | Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis | PEGBELFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT03517540 | Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis | Phase 2 | 193 | 2021-11-12 | Non-alcoholic Steatohepatitis (NASH) | CENICRIVIROC, TROPIFEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT04166773 | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 190 | 2025-01-24 | Nonalcoholic Steatohepatitis | TIRZEPATIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03912532 | Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3) | Phase 2 | 171 | 2025-07-03 | NASH - Nonalcoholic Steatohepatitis | ALDAFERMIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 6 of 1,185 | 2 of 593 | 1,778 | NCT03028740 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 159 of 1,180 | 70 of 589 | 1,769 | NCT03028740 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1 | 11 of 145 | 8 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1 | 23 of 145 | 27 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 7 of 145 | 4 of 144 | 289 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1 | 29 of 145 | 15 of 144 | 289 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-Point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1 | 22 of 144 | 24 of 143 | 287 | NCT02217475 | Trial comparisons |
CVC 150 mg vs Placebo: Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2 | 20 of 215 | 6 of 72 | 287 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2 | 9 of 215 | 1 of 72 | 287 | NCT02217475 | Trial comparisons |
| CVC 150 mg vs Placebo: Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1 | 6 of 144 | 7 of 143 | 287 | NCT02217475 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001395
GET https://conductscience.org/api/diseases/v1/HP_0001395/drugs?page=2